Proposed C Share Issue & DCM

Intl. Biotechnology Trust PLC
16 November 2006









     NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN





             International Biotechnology Trust plc (the 'Company')



             Proposed C Share Issue and Discount Control Mechanism



In the period since 15 November 2005, the share price of the ordinary shares of
the Company has risen from a closing middle market price of 104.5p to 155.5p,
being the closing middle market price on 14 November 2006, an increase of 48.8
per cent. The net asset value of the ordinary shares has risen from 122.37p on
15 November 2005 to 155.97p at the close on 14 November 2006, being the latest
published net asset value per share, a rise of 27.5 per cent. The Company
continues to benefit from the proven management skills of the team at SV Life
Sciences Managers LLP as evidenced by the recent valuation uplifts in the
Company's portfolio of listed and unlisted investments.



In view of this performance and the favourable long-term outlook for the
biotechnology sector, the Company is considering increasing its size through a C
Share issue to provide the Company with additional proceeds to invest, over
time, into, in particular, unquoted biotechnology companies in accordance with
the Company's investment strategy.   Any fundraising would be structured so as
not to be dilutive to existing shareholders' net asset value. The Company will
make a further announcement in due course, including the anticipated size of the
issue.

The Board also announces the introduction of a discount management policy, to
take effect on the completion of the C Share issue, under which the Company will
seek to maintain the discount to the net asset value at which shares, including
the C Shares, are quoted on the London Stock Exchange at no greater than 8 per
cent. Given the nature of the portfolio, the need for the Manager to have access
to any available cash for investment opportunities and any changes in general
market conditions and/or peer group company ratings, it will be necessary for
the Board to review this target discount level from time to time and to maintain
the same at either a narrower or wider level as appropriate.

16 November 2006





Enquiries:

Cenkos Securities plc
William Rogers/Max Hartley                              020 7397 1920

SV Life Sciences Managers LLP
Kate Bingham/Andy Smith                                 020 7421 7070

International Biotechnology Trust plc
John Spedding                                           020 7658 3206

Lansons Communications
Amy Fisher/Henrietta Guthrie                            020 7294 3612






                      This information is provided by RNS
            The company news service from the London Stock Exchange